A pyrazolopyran derivative preferentially inhibits the activity of human cytosolic hydroxymethyltransferase and induces cell death in lung cancer cells by Marani, Marina et al.
Oncotarget4570www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 4
A pyrazolopyran derivative preferentially inhibits the activity of 
human cytosolic serine hydroxymethyltransferase and induces cell 
death in lung cancer cells
Marina Marani1,*, Alessio Paone1,*, Alessio Fiascarelli1, Alberto Macone1, Maurizio 
Gargano1, Serena Rinaldo1, Giorgio Giardina1, Valentino Pontecorvi1, David Koes2, Lee 
McDermott3, Tianyi Yang 4, Alessandro Paiardini5, Roberto Contestabile1, Francesca 
Cutruzzolà1
1 Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza University of Rome, Rome 00185, Italy
2 Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA
3 Department of Pharmaceutical Sciences and Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
4 Department of Chemistry and Biochemistry Cristol 63, University of Colorado, Boulder, CO 80302, USA
5Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, Rome 00185, Italy
*These authors contributed equally to this work
Correspondence to: Francesca Cutruzzolà, e-mail: francesca.cutruzzola@uniroma1.it
 Alessio Paone, e-mail: alessio.paone@uniroma1.it
Keywords: lung cancer, serine hydroxymethyltransferase, pyrazolopyrans, inhibition, apoptosis
Received: July 23, 2015 Accepted: November 25, 2015 Published: December 22, 2015
ABSTRACT
Serine hydroxymethyltransferase (SHMT) is a central enzyme in the metabolic 
reprogramming of cancer cells, providing activated one-carbon units in the serine-
glycine one-carbon metabolism. Previous studies demonstrated that the cytoplasmic 
isoform of SHMT (SHMT1) plays a relevant role in lung cancer. SHMT1 is overexpressed 
in lung cancer patients and NSCLC cell lines. Moreover, SHMT1 is required to maintain 
DNA integrity. Depletion in lung cancer cell lines causes cell cycle arrest and uracil 
accumulation and ultimately leads to apoptosis. We found that a pyrazolopyran 
compound, namely 2.12, preferentially inhibits SHMT1 compared to the mitochondrial 
counterpart SHMT2. Computational and crystallographic approaches suggest binding 
at the active site of SHMT1 and a competitive inhibition mechanism. A radio isotopic 
activity assay shows that inhibition of SHMT by 2.12 also occurs in living cells. 
Moreover, administration of 2.12 in A549 and H1299 lung cancer cell lines causes 
apoptosis at LD50 34 μM and rescue experiments underlined selectivity towards 
SHMT1. These data not only further highlight the relevance of the cytoplasmic isoform 
SHMT1 in lung cancer but, more importantly, demonstrate that, at least in vitro, it is 
possible to find selective inhibitors against one specific isoform of SHMT, a key target 
in metabolic reprogramming of many cancer types.
INTRODUCTION
A major feature distinguishing cancer cells 
from non-malignant cells is their ability to grow and 
divide uncontrollably. To deal with the increasing 
needs caused by active proliferation, cells shift their 
metabolism toward aerobic glycolysis to enhance 
production of biosynthetic intermediates. Indeed, in the 
last few years, reprogramming of cellular metabolism 
has been recognized as a hallmark of cancer [1]. In a 
subset of human tumors, including melanoma, breast 
and non-small-cell lung cancer (NSCLC), a significant 
amount of the glycolytic carbon is redirected into the 
synthesis of serine. Serine anabolism then fuels the 
de novo biosynthesis of purines and pyrimidines and the 
production of antioxidant molecules [2–4]. Thus, serine/
glycine one-carbon (SGOC) metabolism and, in particular, 
serine hydroxymethyltransferase (SHMT), the enzyme 
providing activated one-carbon units by converting 
serine and tetrahydrofolate (H4PteGlu) to glycine and 5, 
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10-CH2-H4PteGlu (ME-THF), represent focal points of the 
metabolic reprogramming of cancer cells.
In humans, two SHMT genes are found: SHMT1, 
which encodes the cytoplasmic isozyme (SHMT1) and 
SHMT2, encoding the mitochondrial one (SHMT2) [5]. 
These two isoforms display a 66% amino acid sequence 
identity. SHMT2 also encodes a second transcript 
SHMT2α that lacks the mitochondrial import signal, and 
is thus localized in the cytoplasm [6]. SHMT2 seems 
preferentially involved in the synthesis of glycine and 
mitochondrial dTMP [7, 8], while SHMT1 and, to a 
lower extent (25%), SHMT2α participate to the synthesis 
of dTMP, undergoing nuclear import during S-phase 
and supplying ME-THF during the thymidylate cycle, 
along with thymidylate synthase (TS) and dihydrofolate 
reductase (DHFR) [9]. SHMT2 has been recently shown to 
be upregulated under hypoxic conditions [10], producing 
glycine and ME-THF and thereby increasing the synthesis 
of NADPH, which is necessary to counteract the increase 
in oxidative stress experienced under low oxygen tension.
SHMT1 polymorphisms have been associated with 
increased lung cancer risk [11]. We recently demonstrated 
that SHMT1 plays a relevant role in lung cancer, as it is 
overexpressed in tissue samples from lung cancer patients 
and NSCLC cell lines. Moreover, knockdown of SHMT1 
in lung cancer cells triggers cell cycle arrest and, during 
DNA replication, uracil accumulation causing apoptosis in 
a p53-dependent manner. Therefore, nuclear localization 
of SHMT1 is required to maintain DNA integrity [12]. 
Lung cancer remains the most common cancer in the 
world, both in term of new cases and deaths because of the 
high case fatality [13]. The role played by SHMT at the 
crossroads of different key metabolic pathways (serine/
glycine and nucleotide/folate metabolism) makes it a 
potential target of novel chemotherapeutic drugs [14–16]. 
Despite its relevance, only a few studies that focus on drug 
design strategies and discovery of compounds that can 
inhibit SHMT have been carried out to date. The search 
for selective serine analogues and amino acid derivatives 
as SHMT inhibitors has not been successful [17].
Antimetabolites, the drugs quenching the effects 
of metabolites on cellular processes, are a landmark in 
anticancer therapy. The only antifolate compounds with 
anticancer activity found to inhibit SHMT, apparently 
irreversibly, were the quite toxic sulphonyl fluoride 
triazine derivatives [18]. Leucovorin (5-CHO-H4PteGlu) 
has been indicated as another inhibitor of both SHMT 
isoforms, with preference for SHMT1 over SHMT2. 
Unfortunately, it cannot be used clinically as an SHMT 
inhibitor, as it is converted to other folic acid derivatives 
(e.g., H4PteGlu) and thus has vitamin activity, equivalent 
to that of folic acid [19]. We have recently identified two 
other antifolates, pemetrexed [20] and lometrexol [21], 
which act in vitro as micromolar inhibitors of SHMT. 
However, these are both multitarget antifolates, approved 
by the US Food and Drug Administration (FDA) for 
the treatment of mesothelioma (in combination with 
cisplatin) and NSCLC. 
A novel set of 338 molecules sharing a 
pyrazolopyran scaffold were recently reported in a 
patent application by BASF AG (WO 2013182472 A1) 
as plant SHMT inhibitors with IC50 values in the low 
micromolar/nanomolar range. Given the key role played 
by plant SHMT in the photorespiration cycle, controlling 
the formyl-transfer between glycine and serine, these 
compounds were suggested primarily as weed killers, 
but have been recommended also as pharmaceutically 
active ingredients for treating or preventing parasitic 
and/or bacterial infections. More recently, it was shown 
that some of those pyrazolopyrans are also active 
against the Plasmodium falciparum SHMT protein [23]. 
These two facts prompted us to test a low and a high 
activity compound from the WO 2013182372 A1 patent 
application against human SHMTs with the objective of 
performing preliminary assessment of the activity and 
potential of this pyrazolopyran class as human SHMT 
inhibitors. We randomly selected compounds 2.2 and 
2.12 (Figure 1) for further experimentation. Here we 
demonstrate that, unlike compound 2.2 that shows a low 
affinity for both human SHMTs, compound 2.12 ((4R)-
6-amino-4-ethyl-4-(3, 5-chlorophenyl)-1H-pyrano[2,3-c]
pyrazole-5-carbonitrile) is able to selectively inhibit 
the human cytoplasmic isoform of SHMT versus the 
mitochondrial one. In addition, treatment of lung cancer 
cells with compound 2.12 induces cell death through the 
activation of apoptosis. Our data open the possibility of 
designing a new generation of effective chemotherapeutic 
agents acting as selective SHMT inhibitors based on this 
scaffold.
RESULTS
Inhibition of SHMT cytosolic and mitochondrial 
isoforms by compounds 2.2 and 2.12
Initially, compounds 2.2 and 2.12 (Figure 1) were 
tested on purified recombinant SHMT1 and SHMT2 
isoforms using a spectrophotometric assay, in which the 
inhibitors and H4PteGlu compete for binding to the same 
site of the enzyme [20, 21]. Both isozymes (5.5 µM) 
were incubated with a saturating concentration of glycine 
(3.0 mM), in the presence of 20 µM H4PteGlu and a 
varying concentration of either compound 2.12 or 2.2. 
The activity of the enzyme was calculated from the 
spectrophotometric measurement of the quinonoid 
intermediate that develops when both glycine and 
H4PteGlu bind to SHMT [20]. The estimated inhibition 
constants (IC50) were: for SHMT1, 154.5 ± 14.4 μM with 
compound 2.2 (Supplemental Figure 1) and 57.9 ± 5.5 μM 
with compound 2.12 (Figure 2A); for SHMT2, 262.8 ± 
48.0 μM with compound 2.2 (Supplementary Figure 1) and 
227.2 ± 38.0 μM with compound 2.12 (Figure 2A). This 
Oncotarget4572www.impactjournals.com/oncotarget
encouraging result with compound 2.12 was confirmed in 
a second inhibition assay using a radioisotopic method, 
with known specificity for SHMT [12], and which 
measures the rate of exchange of tritium from H3-glycine 
to water. In this assay, the enzyme concentration was 
43 nM, H4PteGlu was 20 µM, glycine was 23 µM and 
compound 2.12 concentration varied between 9.75 µM 
and 156 µM. Calculated inhibition constants in the latter 
assay were 59.6 ± 4.6 µM for SHMT1 and 252.8 ± 30.7 
µM for SHMT2 for 2.12 (Figure 2B). Considering the 
ability of 2.12 to selectively target human SHMT1 and the 
high inhibition constant of 2.2, we decided to focus our 
attention on 2.12 in subsequent experiments.
Predicted binding mode of 2.12 to human SHMT1
Based on the recently solved crystal structure 
of Plasmodium vivax SHMT in complex with the 
pyrazolopyran compound 5-{3-[(4S)-6-amino-5-cyano-
3-methyl-4-(propan-2-yl)-2, 4-dihydro pyrano[2, 3-c]
pyrazol-4-yl]-5-cyanophenyl}thiophene-2-carboxylate 
([23] PDB: 4TMR), a template-based docking of 2.12 was 
carried out into the active site of human SHMT1 (Figure 
3A). Compound 2.12, like the pyrazolopyran in the 4TMR 
crystal structure, is predicted to occupy the H4PteGlu 
binding site of human SHMT1. The binding location of 
2.12 was confirmed via low-resolution crystallographic 
data (4.2 Å resolution) of human SHMT1 in complex 
with 2.12, which showed a positive electron density, up to 
5.0 sigma, in agreement with the docking results (Figure 
3B). According to the docking results, 2.12 interacts with 
human SHMT1 showing a net preference for the (S)-
absolute configuration, as also observed in Plasmodium 
vivax SHMT [23] (Figure 3C). 
In our model, a polar environment encloses the 
pyrazolopyran moiety of 2.12. The backbone of Thr388 
forms a hydrogen bond with the cyano group and a 
bidentate interaction is formed between the amino 
group of 2.12 and the backbone carbonyls of Leu143 
and Gly147. The N2 of the pyrazole moiety undergoes 
hydrogen bonding to Glu75. A small pocket formed by 
residues Asn385-Asn387 is filled by the ethyl group at the 
chiral center of 2.12. The 3, 5-substituted phenyl group 
consists of two hydrophobic Cl atoms, one pointing to a 
small lateral pocket and making contact with Tyr83 and 
Lys386, and the other one further extending along the 
active site channel and engaging in nonpolar interactions 
along the channel.
Involvement of a flexible loop in 2.12 binding
The IC50 of 2.12 for Plasmodium falciparum SHMT 
is 280 nM ([23]; compound number 44 in table S1 of 
Supporting Information). In order to derive a structure-
based rationale for the observed difference of affinity 
displayed by 2.12 for human and Plasmodium SHMT, 
we compared the binding mode of 2.12 to the active 
sites of both enzymes, using as reference the crystal 
structure of Plasmodium vivax SHMT in complex with a 
pyrazolopyran compound ([23] PDB: 4TMR; 83% identity 
with Plasmodium falciparum SHMT) (Figure 3C). As 
SHMT is an enzyme of pivotal importance for nucleotide 
synthesis, it is not surprising that its overall structure, 
and in particular the residues composing the active 
site, are well conserved through evolution. Residues of 
Plasmodium SHMT binding to the pyrazolopyran scaffold 
[23] are invariant in human SHMT1 and SHMT2. The 
only exception is Thr183 of Plasmodium SHMT, which 
is conservatively replaced by Ser203 in human SHMT1 
(Ser205 in SHMT2). The difference of affinity displayed 
by 2.12 for human and Plasmodium falciparum SHMTs 
may in part be due to this Ser/Thr substitution. Another 
key structural difference between Plasmodium vivax 
SHMT and human SHMT1 lies in the loop region formed 
by the residues Asn387-Ser399 in human SHMT1 and the 
equivalent residues Asn356-Ser368 in Plasmodium vivax. 
Figure 1: Chemical structure of compounds 2.2 and 2.12.
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This region, which forms part of the THF binding cleft, 
appears to be flexible and has a different conformation 
in these structures (Figure 3D). In the docked model, the 
Plasmodium vivax SHMT Asn356-Ser368 loop enclose the 
hydrophobic Cl atoms of 2.12 in an apolar environment 
(which also includes Tyr63) more effectively than the 
human SHMT1 and SHMT2 loop. The different residue 
composition and conformation that this loop assumes may 
explain, from a structural point of view, the difference 
in affinity observed for 2.12. The dynamics of this loop 
region may also contribute: in molecular dynamics 
simulations, this loop displays slightly greater flexibility in 
SHMT2, as measured by the root mean squared deviation 
in atomic coordinates from the initial structure. Increased 
flexibility in the unbound structure implies an increased 
entropic penalty upon stabilization by ligand binding. 
Perhaps more importantly, as shown in Figure 3E, the 
two isoforms sample a different conformational space 
of this loop, with SHMT1 displaying a greater tendency 
towards enclosing the binding pocket. This indicates 
that in SHMT1 this loop may be predisposed toward 
conformations that interact with the dichlorobenzene ring 
that distinguishes 2.12 from 2.2.
Inhibition of SHMT activity in living cells 
Several recent papers describe SHMT2 upregulation 
in several cancer cell types, including colon and breast 
[24, 25], underlying the relevance of this isoform in 
the metabolism of specific cancer cells, where it is 
upregulated possibly to counteract redox stress. On the 
other hand, we recently demonstrated the crucial role of 
SHMT1 for the survival of lung cancer cells; albeit being 
overexpressed also in these cells [12], SHMT2 appears to 
play a minor role. These data suggest that the two SHMT 
isoforms may have distinct functions in different types of 
tumours. To test the ability of compound 2.12 to inhibit 
SHMT in cancer cells, we measured the SHMT activity in 
living cells by a modified version of the above-described 
radioisotopic assay [26]. Together with lung cancer cell 
lines A549 and H1299, which over-express both SHMT1 
and SHMT2 [12], we also used COLO320 cells that over-
Figure 2: Activity inhibition on purified SHMTs by compound 2.12. The activity of cytosolic (black symbols) and mitochondrial 
(red symbols) SHMT isoforms was measured in the presence of increasing concentrations of compound 2.12. Values are the average ± 
standard deviation of three independent measurements. Continuous lines through the experimental points are those obtained from the 
least square fitting of data to equation 1. Two different competitive binding assays were carried out. (A) One assay was based on the 
spectrophotometric measurement of the quinonoid intermediate that develops when both glycine and H4PteGlu are bound to the enzyme. 
Estimated inhibition constants were 57.9 ± 5.5 μM for SHMT1 and 227.2 ± 38.0 μM for SHMT2. (B) The results shown are based on a 
radioisotope assay that exploits the capability of SHMT to catalyse the exchange of glycine 2-pro-S proton with the solvent. With this assay, 
the calculated inhibition constants were 59.6 ± 4.6 mM for SHMT1 and 252.8 ± 30.7 mM for SHMT2.
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express SHMT2 but not SHMT1 (Supplemental Figure 2). 
The cultured cells were pre-treated with 2.12 or DMSO 
(the solvent in which 2.12 was dissolved) for 1 hour. 
Figure 4A shows that 2.12 inhibits the total SHMT activity 
in cancer cell lines in a dose dependent manner and that 
SHMT activity in lung cancer cells is much more sensitive 
to compound 2.12 (IC50 between 11.5 and 34 µM) than in 
colon cancer cells (IC50 between 34 and 200 µM). These 
data are in agreement with the higher affinity of 2.12 for 
SHMT1 observed in tests with purified proteins.
To validate the ability of 2.12 to inhibit SHMT1 
in lung cancer cells, we used gas chromatography/mass 
spectrometry to evaluate the glycine and serine content 
in A549 and H1299 cells treated or not with 2.12. Data 
in Figure 4B show a strong decrease in glycine content 
in both cells lines after 2.12 treatment. The levels of 
serine seem to be slightly increased but this variation is 
not statistically significant. Overall, data suggest a direct 
effect of 2.12 compound on SHMT(s) in living cells.
Treatment with 2.12 induces cell death in cancer 
cells
We previously demonstrated that RNA interference 
(RNAi) against SHMT1 induces apoptosis in lung 
cancer cell lines [12], via the misincorporation and 
Figure 3: Template-based docking of 2.12 into the active site of SHMTs. (A) Docked 2.12 to human SHMT1, 2.12 and 
PLP-Glycine complex are depicted as purple and green sticks, respectively. Protein-ligand polar interactions are shown as black dashes, 
distances are given in Å. Residue numbering refers to SHMT1. (B) Docked 2.12 superposed with the low-resolution (4.2 Å) difference 
electron density map (contour level at 3.0 sigma) of SHMT1 co-crystallized with 2.12. The difference electron density map is shown as 
green mesh. (C) Comparison of 2.12 docked to SHMT1 (white) and pvSHMT (pink). Atom coloring is the following: N blue, O red, P 
orange. The backbone of SHMT1 is also shown, as reference. (D) Comparison of the loop region (residues 386-399) of human SHMT1 
(white), Plasmodium vivax SHMT (green) and human SHMT2 (mitochondrial, pink). Only Cα traces are shown. 2.12 is also shown, as pink 
sticks. (E) Loop conformations sampled during a 100 ns molecular dynamics simulation of apo human SHMT1 (white) and SHMT2 (pink).
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accumulation of uracil in DNA. To test the ability of the 
SHMT inhibitor 2.12 to induce cell death, we treated the 
A549, H1299 and COLO320 cells with different doses of 
2.12 for 24 h, 48 h and 72 h and performed trypan blue 
exclusion and XTT assays.
Figure 5 shows that 2.12 induces cell death in all 
the cell lines tested, as evident in both the trypan blue 
exclusion assay, which evaluate dead cells by looking at 
cell membrane integrity (Figure 5A) and the XTT, which 
highlights cells with active mitochondria (Figure 5B). Both 
assays, although with slightly different numbers due to the 
different experimental approaches, indicate that the Lethal 
Dose50 (LD50) for lung cancer cells is around 34 µM, while 
the LD50 for COLO320 cells is between 46 and 92 µM. 
These data demonstrate that a lower concentration of 2.12 
is needed to kill A549 and H1299 cells compared to the 
COLO320 cell line. 
2.12 induces cell death through an apoptotic 
process
To clarify if the 2.12-mediated induction of lung 
cancer cell death is due to the activation of an apoptotic 
process, we used PI and Annexin-V staining. Figure 6A 
and 6B shows that 2.12 induces the accumulation of a 
subG1 population of A549 and H1299 lung cancer cells 
after 48 hours of treatment, clearly indicating an apoptotic 
phenomenon, with a strong induction (around 40% for 
A549 and 25% for H1299) at the concentration of 34 
µM. Figure 6C and 5D shows the same cell lines after 
treatment with 2.12 (34 µM for 48 h) together with the 
control untreated samples, both stained with annexin-V. 
The accumulation of cells in the population Annexin-V 
positive/7-AAD negative after treatment with 2.12 
confirms that the apoptotic mechanism is involved. 
Rescue of 2.12-treated lung cancer cells by 
metabolites providing one-carbon units
It is well known that adding selected metabolites 
can rewire the cellular metabolism, thus bypassing 
deficiencies in a given enzyme, as previously shown for 
SHMT2 [25]. We employed a similar approach to evaluate 
whether the apoptotic effect induced by compound 2.12 
was due to the inhibition of the SHMT SER/GLY activity. 
The 2.12-treated (34 µM) or untreated A549 and H1299 
lung cancer cells were grown in a minimal medium 
supplemented or not with serine, glycine and 5-formyl-
THF (used in these experiments for its higher stability 
compared to THF) [21]. The apoptotic rate was evaluated 
using PI and annexin-V/7AAD staining. The data in Figure 
7A and 7B (PI staining) and 7C and D (Annexin-V/7AAD 
staining) demonstrate that the 2.12-induced apoptotic 
effect is partially rescued (~ 28%) if the cells are grown in 
the supplemented medium, suggesting that SHMT SER/
GLY activity is likely involved in the observed apoptotic 
effect.
To validate the selectivity of 2.12 for SHMT1 we 
used a parallel strategy, involving the over-expression 
of this protein in the selected cell lines starting from 
a plasmid-borne gene; SHMT1 overexpression was 
confirmed by western blot (Supplemental Figure 3). The 
effect of compound 2.12 (34 µM) on cells transfected with 
the plasmid encoding SHMT1 was evaluated by studying 
Figure 4: Inhibition of SHMTs activity in living cells. (A) SHMTs activity was measured in A549 and H1299 lung cancer cell 
lines and COLO320 colon cancer cell line after treatment with 2.12 at different concentrations. The inhibitory effect of 2.12 occurs in a 
dose dependent manner. The histogram represents mean ± standard deviation of two independent replicates. (** = P ≤ 0.001). (B) Gas-
chromatography/mass-spectrometry semi quantitative evaluation of glycine and serine content in A549 and H1299 cells treated or not with 
2.12 (25 mM for 24 h). The mean ± standard deviation of three independent experiments is shown in the histogram (* = P ≤ 0.05). 
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cell viability (XTT assay). Figure 7E shows that SHMT1 
overexpression is able to partially rescue (~30%) the death 
effect induced in A549 cells by treatment with 2.12 (34.5 
and 46 µM) indicating that SHMT1 is a direct target of 
2.12. Unfortunately, when using H1299 cells in the same 
experiment, we did not reach statistical significance 
despite several repeats, although we observed a similar 
trend (Figure 7F). We have previously shown that the 
expression of SHMT1 and SHMT2 are interconnected and 
there are differences in the response to SHMT modulation 
in A549 and H1299 lung cancer cell lines [12]. SHMT1 
overexpression in H1299 cells causes a strong down-
regulation of SHMT2 (Supplemental Figure 4), which 
is less evident in A549 cells. This crosstalk between 
the expression of the two SHMT isoforms, particularly 
in H1299 cells, may have ultimately prevented a clear 
response with this cell line in the above experiments.
DISCUSSION
SHMTs are key enzymes in the metabolism of 
several cancer cell types, including lung, colon and 
breast [12, 25]. They occupy a key position in the 
complex SGOC pathway, controlling the production of 
DNA bases, metabolic intermediates and antioxidant 
molecules that are fundamental for rapidly proliferating 
Figure 5: Cell death induction after treatment with 2.12. A549, H1299 and COLO320 cancer cell lines were treated for 24 h, 
48 h and 72 h with increasing concentrations of 2.12 and cell death was evaluated by trypan blue exclusion assay (A) and XTT assay (B). 
All data represent mean ± standard deviation of at least 3 independent experiments. (* = P ≤ 0.05) 
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cells. In a recent patent application by BASF AG (WO 
2013182472 A1) several pyrazolopyran compounds were 
disclosed as inhibitors of Arabidopsis thaliana SHMT 
activity. Moreover, a recent paper demonstrated that 
molecules from the pyrazolopyran series are also active 
against the SHMT activity of Plasmodium falciparum. 
In this work we have selected two representatives of the 
pyrazolopyran scaffold and tested in vitro their ability to 
block the activity of human SHMTs. Our results show that 
compound 2.12 behaves as an antifolate, binding to the 
THF site in human SHMTs, but is less active towards the 
human enzymes than pfSHMT. This demonstrates that, 
although SHMTs from different sources are structurally 
very similar, small differences can have a large effect 
on ligand and/or cofactor binding and on inhibitory 
potential. Our experiments also show that among human 
SHMT isoforms, SHMT1 is more effectively inhibited by 
compound 2.12 than SHMT2. Our in vitro data suggests 
that it may be possible to design pyrazolopyran-type 
inhibitors of human SHMT which selectively inhibit one 
isoform of the enzyme over the other.
The ability of 2.12 to inhibit human SHMTs was 
also demonstrated in living cells. Our experiments do not 
allow us to assess the individual contribution of the two 
isoforms to the overall SHMT activity in cells. However, 
we were able to demonstrate that treatment with 2.12 led to 
significant decrease of glycine levels in lung cancer cells. 
This result is in agreement with an inhibitory effect of 2.12 
on SHMT activity. A concomitant large increase in serine 
concentration would also be expected, yet we observed 
only a small, non-significant increase of serine. We believe 
that this is due to serine consumption by the activity of 
SHMT2 in the mitochondria which is probably unaffected 
by 2.12, given the observed low inhibitory effect of this 
compound on SHMT2. Serine would therefore enter the 
mitochondria and be consumed in the SHMT2-catalysed 
Figure 6: Activation of apoptotic process causes 2.12-mediated cell death. Apoptotic induction analysis by (A and B) 
PI staining after 2.12 treatment at different concentrations for 48 h and (C and D) AnnexinV/7-ADD staining after 2.12 treatment at 
34 µM for 48 h in A549 and H1299 cell lines. Data in B and D represent mean ± standard deviation of at least 3 independent replicates. 
* = P ≤ 0.05, * = P ≤ 0.01.
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conversion into glycine and ME-THF. In turn, glycine 
would be irreversibly oxidized to CO2 and ME-THF by 
the mitochondrial glycine cleavage system. The formate 
derived from ME-THF would then be exported to the 
cytosol where it is converted into folate-activated carbon 
units [27, 28]. Our previously published data demonstrate 
that, differently from other cancer cell types, lung cancer 
cells are extremely sensitive to SHMT1 levels [12]. RNAi 
against this protein induces apoptosis at a higher level 
compared to RNAi against SHMT2, which is generally 
considered a more suitable target for chemotherapy [25]. 
Considering the ability of 2.12 to preferentially inhibit 
human SHMT1, we treated lung and colon cancer cell 
types with this compound and studied the induction of cell 
death. We demonstrated that lung cancer cells are more 
sensitive to 2.12 when compared to colon cancer cells, and 
we suggest that this difference could be ascribed, at least 
in part, to the differential expression of SHMT1 in these 
cell lines. 
A more detailed analysis demonstrated that the 
2.12-induced cell death is attributable to an apoptotic 
signal. Rescue experiments have been previously used 
to confirm the ability of an inhibitor to block an enzyme 
in a specific metabolic process. In our experiments, 
supplementation of glycine, serine and 5-formyl-THF 
promotes a ~30% recovery from the 2.12-induced 
apoptosis and suggests that 2.12 inhibits SHMT activity 
in living cells. Recovery to the same extent (~about 30%) 
was also observed after overexpression of SHMT1 in 
2.12-treated A549 lung cancer cells. This observation 
Figure 7: Effect of selected metabolites on cells 2.12-treated and selectivity of 2.12 against SHMT1. Apoptotic rate 
evaluation of A549 and H1299 treated or not with 2.12 and grown in minimal essential medium supplemented or not with serine, glycine 
and 5-formyl-THF. (A) and (B) PI staining, (C) and (D) AnnexinV/7-ADD staining. (E) and (F) XTT assay on A549 and H1299 respectively 
transfected with the indicated plasmid and treated or not with 2.12 34 mM for 48 hours. Data in B, D, E and F represent mean ± standard 
deviation of at least 3 independent experiments. * = P ≤ 0.05.
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correlates with the results obtained with the medium 
supplementation experiments mentioned above. A more 
complex picture was observed with 2.12-treated H1299 
cells in which SHMT1 was overexpressed to counteract 
the inhibitory effect of 2.12. In these experiments a rescue 
trend similar to the one observed with the A549 cells was 
observed, but it did not reach statistical significance. The 
lack of a clear rescue effect with the H1299 cell line may 
be due to the reduction of SHMT2 expression that has 
been observed in H1299, but not in the A549 SHMT1 
overexpressing cells, that may alter the overall flux of 
metabolites in the SGOC pathway. 
In conclusion, the results of this work demonstrate 
that 2.12 is able to induce a strong apoptotic signal in 
lung cancer cells. At this stage we cannot exclude that 
2.12 may inhibit enzymes other than SHMT involved in 
the folate cycle and further studies will be carried out to 
evaluate other possible target(s). Moreover, the present 
data support the potential of a differential inhibition of the 
two human SHMT isozymes with compounds based on the 
pyrazolopyran scaffold.
MATERIALS AND METHODS
Compounds 2.12 and 2.2
Compounds 2.2 and 2.12 were prepared as described 
in WO2013/182472 A1 [22].
Crystal structure with 2.2 and 2.12
Needle-shaped crystals were obtained by mixing 
equal volumes of a solution containing 50 µM human 
SHMT1, 40 mM glycine and 400 µM of 2.12 (or 2.2) 
inhibitor with a crystallization solution containing tri-
potassium citrate and PEG 3350. A low-resolution 
(4.2 Å) complete data-set, collected at ESRF ID23.1 
beamline, was processed with XDS [29] and phased by 
molecular replacement with MOLREP [30] using SHMT1 
structure as template PDB code: 1BJ4 [15]. The space 
group was P212121 with unit cell constants; a = 140.38, 
b = 140.52, c = 268.39. The crystals were twinned with 
twin operator -k,-h,-l originating a pseudo tetrameric 
symmetry. Final model consisted of 8 mol/AU and was 
refined in REFMAC5 [31] to a final Rwork and Rfree of 
32.7 and 33.7, respectively. The resolution of the electron 
density maps was too low to build a reliable model of 
the inhibitor, however a positive electron density up to 5 
sigma was observed in the Fobs−Fcal map.
Protein purification
SHMT1 and SHMT2 were purified as described in 
[32].
Inhibition experiments on purified recombinant 
SHMT isoforms
Inhibition of SHMT activity by compound 2.12 
was tested using competitive binding assays in which the 
antifolate competes for binding with H4PteGlu. The first 
assay is based on the spectrophotometric measurement 
of the quinonoid intermediate that develops when both 
glycine and H4PteGlu bind to SHMT, forming an enzyme-
glycine-folate ternary complex [20]. The quinonoid 
intermediate, which yields an intense absorption band with 
a maximum at around 500 nm, derives from deprotonation 
of glycine, but it accumulates to a measurable extent 
only when a folate ligand is also bound to SHMT and a 
ternary complex is formed [33]. Therefore, absorbance at 
500 nm is proportional to the fraction of enzyme present 
as ternary complex. The assay was carried out at 30°C in 
20 mM KPi buffer pH 7.2. Compound 2.12 was dissolved 
in pure DMSO. The effect of DMSO concentration on 
quinonoid development was analysed and found to be 
negligible up to 20% DMSO (v/v). In all inhibition 
assays, DMSO final concentration was 5% (v/v) and 
H4PteGlu was added as last component. After a rapid 
manual mixing, the absorbance change at 500 nm was 
measured. All measurements were performed in triplicate. 
Inhibition curves were fitted to Eq. 1, in which [I] is the 
concentration of the inhibitor, to obtain the observed 
inhibition constants (Ki).
Equation 1
% ( [ ]
[ ]
)Activity I
I Ki
= × −
+
100 1
Fitting of data was performed with the software 
PRISM (GraphPad, La Jolla, CA, USA). The second 
radioisotope assay was based on the capability of SHMT 
to catalyse the exchange of the pro-2S proton of glycine 
with solvent [26]. SHMT activity was determined by 
incubating 23 mM [2−3H]glycine (2 × 109 dpm µmol−1) 
and 20 mM H4PteGlu with increasing concentrations 
(from 9.75 to 156 mM) of compound 2.12 in 70 µl of 
20 mM potassium phosphate buffer pH 7.2. Control 
reactions were performed to correct for background 
exchange by the addition of 0.5 mM 5-CHO-H4PteGlu. 
Reactions were started by the addition of glycine and 
incubated at 30°C for 2 h. After incubation, reactions were 
stopped by the addition of 3% (w/v) trichloroacetic acid 
and treated as previously detailed [26] so as to remove 
radiolabeled glycine and measure radioactivity in the 
solvent. All measurements were performed in triplicate.
Inhibition experiments on living cells
SHMT activity measurements on living cells were 
based on the radioisotope assay explained above. A549, 
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H1299 and COLO320 cell lines grown in complete 
medium RPMI-1640 were detached using trypsin, 
centrifuged and suspended twice in 2 ml of PBS buffer 
to eliminate the growth medium; 100 ml aliquots of cell 
suspension were incubated with increasing concentrations 
of compound 2.12 (from 9 to 315 mM) at 37°C for 2 h. 
Glycine (23 mM) was then added to the samples, which 
were further incubated for 4 hours at 37°C. At this point, 
samples were centrifuged to remove cells, reactions were 
stopped by the addition of 3% (w/v) trichloroacetic acid 
and treated as previously detailed [26] so as to remove 
radiolabeled glycine and measure radioactivity in the 
solvent. Control reactions were performed to correct for 
background exchange (these samples did not contain cells) 
and to measure 100% of activity (these sample did not 
contain the inhibitor). All measurements were performed 
in duplicate.
Docking of 2.12 to SHMT1
The crystal structure of SHMT1 in its biologically 
active tetrameric form, and in complex with PLP as 
internal aldimine [15], was used as a starting point to 
model the “closed” form of the enzyme in complex with 
PLP-glycine, as previously described [20]. The Dundee 
PRODRG2 Server was used to build the energy minimized 
three-dimensional structure of 2.12 [34]. Template-based 
molecular docking was carried out by means of Molegro 
Virtual Docker (MVD) software (®CLCbio). Flexible 
torsions of 2.12 were automatically detected by MVD, 
and manually checked for consistency. The obtained three-
dimensional structure of human SHMT1 was prepared by 
automatically assigning bond orders and hybridization, and 
adding explicit hydrogens, charges and Tripos atom types. 
A search space of 15 Å radius, centered on the active site 
cavity, was used for docking. The pyrazolopyran skeleton 
of CAS 1508291-70-0 was taken as pharmacophoric group 
for template-based dockings [22]. In the latter, if an atom 
of the ligand matches a group definition, it is rewarded 
by using a weighted score that depends on its distance to 
the group centers. The grid-based MolDock score with 
a grid resolution of 0.30 Å was used as scoring function 
and MolDock SE was used as docking algorithm [35]. 
For each ligand, ten runs were defined. Similar poses 
(RMSD ≤ 1.0 Å) were clustered, and the best scoring one 
was taken as representative. Other docking parameters 
were fixed at their default values. After docking, energy 
optimization of hydrogen bonds was performed.
Molecular dynamics
Molecular dynamics simulations were performed 
using version 14 of Amber with the Amber14ffsb force 
field. Monomeric structures of human SHMT1 (PDB 
1BJ4) and SHMT2 (PDB 4PVF) were assembled into 
dimer structures using the fully resolved mouse dimeric 
structure (PDB 1EJI) as a template. Missing loops in the 
SHMT2 structure (distant from the active site) were built 
using I-TASSER [37]. Systems were solvated in a TIP3P 
octahedral 12Å water box and two rounds of minimization 
and molecular dynamics equilibration were applied prior 
to the production run of 100 ns. Complete simulation 
parameters are provided in the supplementary information.
Cell lines
COLO320 were purchased from ATCC (Manassas, 
VA, USA). A549, H1299 and COLO320 cancer cells 
were grown in RPMI-1640 medium supplemented with 
2 mM L-glutamine, 100 IU/ml penicillin/streptomycin, 
and 10% fetal calf serum (FCS; Sigma-Aldrich, St Louis, 
MO, USA). The rescue experiments were performed 
in A549 and H1299 cancer cells grown in Miminum 
Essential Medium Eagle (Sigma-Aldrich) supplemented 
with 1X MEM Vitamin Solution, 2 mM L-glutamine, 
25 mM glucose, 10% fetal bovine serum dialyzed, 100 IU/ml 
penicillin/streptomycin and 0.4 mM serine, 0.4 mM glycine 
and 0.02 mM 5-formyl-THF (Merck Eprova AG).
Chemicals and reagents
2-(4-chlorophenyl)ethylamine, ethyl chloroformate, 
diethyl ether, ethyl acetate and dichloromethane were 
obtained from Sigma-Aldrich. 
Sample extraction and derivatization
Serine and Glycine were analyzed according to the 
method of Gao et al. with slight modification [38]. Cell 
(A549 and H1299) pellets were suspended in 100 µl of 
chloroform/methanol/water (1:3:1 ratio) at 4oC and mixed 
vigorously to break up the pellet. After centrifugation for 
3 min (13,000 g at 4oC) the supernatant was collected, 
dried under N2, resuspended in 500 µl of water and spiked 
with 20 µl of 0.7 mM 2-(4-chlorophenyl)ethylamine. The 
first step of derivatization was performed by adding 350 µl 
of ethanol/pyridine (6:1) and 50 µl of ethyl chloroformate 
(ECF). The reaction mixture was then vortexed for 30 
sec and ultrasonicated for 60 sec to increase the speed of 
reaction at room temperature. The derivatization products 
were extracted with 700 µl of n-hexane for 60 sec and 
centrifuged for 5 min at 3000 rpm. The organic layer was 
removed and the aqueous phase was adjusted to pH ≥12 
with 100 µl 7M NaOH. The second derivatization step 
was performed by adding further 50 µl of ECF and 700 µl 
of n-hexane. The reaction mixture was again vortexed for 
30 sec, ultrasonicated for 60 sec, and centrifuged at 3000 
rpm for 10 min. The organic layers were combined, dried 
under N2, resuspended in dichloromethane and analyzed 
by GC/MS.
Oncotarget4581www.impactjournals.com/oncotarget
Gascromatography-mass spectrometry
GC-M analyses were performed with an Agilent 
6850A gas chromatograph coupled to a 5973N quadrupole 
mass selective detector (Agilent Technologies, Palo 
Alto, CA, USA). Chromatographic separations were 
carried out with an Agilent HP5ms fused-silica capillary 
column (30 m × 0.25 mm i.d.) coated with 5%- phenyl-
95%-dimethylpolysiloxane (film thickness 0.25 μm) as 
stationary phase. Injection mode: splitless at a temperature 
of 280°C. Column temperature program: 80°C (2 min) 
ramped to 140°C at a rate of 10°C/min, to 240°C at a rate 
of 4°C/min, to 280°C at a rate of 10°C/min and held for 
5 min. The carrier gas was helium at a constant flow of 
1.0 ml/min. The spectra were obtained in the electron 
impact mode at 70 eV ionization energy; ion source 280°C; 
ion source vacuum 10−5 Torr. MS analysis was performed 
simultaneously in TIC (mass range scan from m/z 50 to 
600 at a rate of 0.42 scans s−1) and SIM mode. GC-SIM-
MS analysis was performed selecting the following ions: 
m/z 102 for glycine, m/z 114 for serine and m/z 227 for 3, 
4-dimethoxybenzoic acid (internal standard).
RNA extraction and real-time qRT–PCR analyses
Total RNA was extracted using TRIzol reagent 
(Invitrogen) following the manufacturers instruction and 
1 μg was used for the reverse transcription reaction by 
using a SuperScript First-Strand Synthesis System Kit 
(Invitrogen). One microliter of the 1:50 dilution of the 
complementary DNA was used for qRT–PCR analysis 
performed in triplicate for each sample using KAPA Sybr 
Fast universal qPCR Kit following the manufacturer 
instructions. Reactions were performed by Stratagene 
MX3000P (Stratagene, La Jolla, CA, USA). Primers used 
have been previously reported [12].
Western blot analysis
Cell lysates were prepared in 8 M urea (Sigma-
Aldrich) and protein concentration was determined by 
Biorad Protein Assay (Bio-Rad, Munchen, Germany). 
Lysates were subjected to SDS–polyacrylamide gel 
electrophoresis and were transferred onto a nitrocellulose 
membrane then saturated with 5% non fat dry milk 
in Tris-buffered saline with 0.1% Tween-20 for 1 h at 
room temperature. Membranes were incubated with 
primary antibody overnight at 4°C and subsequently 
with horseradish peroxidase-conjugated secondary 
antibody for 1 h at room temperature. Membranes were 
washed with Tris-buffered saline with 0.1% Tween-20 
and ECL reagent (Millipore) was used for detection by 
chemiluminescence system Chemidoc MP Imaging 
System (Bio-Rad). Antibody anti-SHMT1 were from 
Cell Signaling Technology (Danvers, MA, USA), the 
secondary antibody anti-rabbit were from Abbiotec (San 
Diego, CA, USA), antibody anti-SHMT2, -β-actin and 
the secondary antibodies anti-goat and -mouse were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Trypan blue exclusion assay
The cells were harvested and washed in cold PBS 
two times, following the addition of a 0.4% (w/v) trypan 
blue solution (Sigma-Aldrich), cells were counted using 
a Burker chamber (Hirschmann, Germany) under an 
Axioskop 2 plus microscope (Carl Zeiss Microscopy, 
Switzerland). Cells staining with trypan blue dye were 
counted as nonviable.
XTT assay
In order to determine the percentage of viable 
cells this assay employs 2, 3-Bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT). 
Only in living cells are mitochondria capable of reducing 
XTT to form an orange colored dye. Therefore, the 
concentration of the dye is proportional to the number of 
metabolically active cells. Approximately 1200 cells/well 
were plated in 96-well dishes in complete medium RPMI-
1640. After 24 h, 48 h and 72 h cells were treated for 
72 h, 48 h and 24 h by adding complete medium and 2.12 
compound at different concentrations. Each test includes 
a blank containing complete medium without cells and 
a negative control made up of 2.12 untreated cells. XTT 
mix reaction (AppliChem GmbH, Darmstadt, Germany) 
was prepared and then added to cell cultures according 
to the manufacturer’s recommendations. After 3 h in 
CO2 incubator at 37°C, the absorbance of samples was 
measured by a spectrophotometer Appliskan Multimode 
Microplate Reader (Thermo Scientific, Waltham, MA 
USA) at a wavelength of 470 nm. In order to measure 
non-specific reading the absorbance of samples was 
measured also at a wavelength of 690 nm and then 
subtracted from the 470 nm measurement to measure 
reference absorbance. The percentage of metabolically 
active cells was calculated according to the following 
formula ((Abs sample – Abs Blank)/(Abs Neg Control – 
Abs Blank)) × 100.
Apoptosis assay
For PI staining, cells were detached with trypsin, 
washed with cold PBS plus 5% FCS and then fixed in 
70% ethanol for 24 h. After washing with PBS, cells 
were incubated with 1 μg/ml PI for 3 h at 25°C before 
cytometric analysis by BD Accuri C6 Flow Cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA). Results 
were analyzed with BD Accuri C6 software and were 
presented as a percentage of specific apoptosis determined 
using the following formula: ((% apoptotic cells in 
experimental sample–% apoptotic cells in control sample)/
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(100–% apoptotic cells in control sample) × 100). For 
AnnexinV staining: cells were detached with trypsin, 
washed with PBS–5% FCS and then placed in binding 
buffer (Pharmingen, San Diego, CA, USA) to which 
7-amino-actinomycin D (7-AAD) and AnnexinV-APC 
(Pharmingen) were added prior to cytometric analysis. 
Cells were considered apoptotic when Annexin-V-APC 
positive and 7-AAD negative.
Cell transfection
Transient transfection experiments were carried 
out by seeding cells (1 × 105 cells/plate) in 6-well 
dishes in complete medium RPMI-1640. Transfection 
was performed adding equal amount of pCDNA and 
pCDNA_SHMT1 (pSHMT1) plasmids 24 h after plating 
using Lipofectamine 2000 reagent in Optimem medium 
(Invitrogen). Optimem medium with plasmids was 
replaced with complete medium RPMI-1640 after 6 h and 
the evaluation of protein expression levels was performed 
by harvesting cells at 48 h after transfection.
Statistical analysis
Statistical differences were determined either 
by Student’s t-test for paired samples or by one-way 
analysis of variance followed by Student’s t-test with the 
Bonferroni correction. P ≤ 0.05 was considered significant.
ACKNOWLEDGMENTS
We gratefully thank Dr. Michele Milella for 
providing lung cancer cell lines used in this work. We 
are also grateful to Merck Eprova AG, Schaffhausen, 
Switzerland, for kindly providing us with pure H4PteGlu 
and 5-CHO-H4PteGlu.
GRANT SUPPORT
Funds from Associazione Italiana Ricerca sul 
Cancro to FC (AIRC-IG2012 n. 13150), from Regione 
Lazio (prog. FILAS-RU-2014–1020), from Fondazione 
Italiana Ricerca sul Cancro to MM (Triennal FIRC 
Fellowship Rif. 14843), from Sapienza University of 
Rome to A. Paiardini (C26A149EC4) and from the 
Winters Foundation to L. McDermott and D. Koes are 
gratefully acknowledged.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
 1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next 
generation. Cell. 2011; 144:646–674.
 2. Mayers JR, Vander Heiden MG. Famine versus feast: 
understanding the metabolism of tumors in vivo. Trends 
Biochem Sci. 2015; 40:130–140.
 3. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, 
Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen 
T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, et al. 
Phosphoglycerate dehydrogenase diverts glycolytic flux and 
contributes to oncogenesis. Nat Genet. 2011; 43:869–874.
 4. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim 
D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha 
AK, Chen WW, Barrett FG, Stransky N, et al. Functional 
genomics reveal that the serine synthesis pathway is 
essential in breast cancer. Nature. 2011; 476:346–350.
 5. Garrow TA, Brenner AA, Whitehead VM, Chen XN, 
Duncan RG, Korenberg JR, Shane B. Cloning of human 
cDNAs encoding mitochondrial and cytosolic serine 
hydroxymethyltransferases and chromosomal localization. 
J Biol Chem. 1993; 268:11910–11916.
 6. MacFarlane AJ, Liu X, Perry CA, Flodby P, Allen 
RH, Stabler SP, Stover PJ. Cytoplasmic serine 
hydroxymethyltransferase regulates the metabolic 
partitioning of methylenetetrahydrofolate but is not 
essential in mice. J Biol Chem. 2008; 283:25846–25853.
 7. Pfendner W, Pizer LI. The metabolism of serine and glycine 
in mutant lines of Chinese hamster ovary cells. Arch 
Biochem Biophys. 1980; 200:503–512.
 8. Anderson DD, Quintero CM, Stover PJ. Identification of a 
de novo thymidylate biosynthesis pathway in mammalian 
mitochondria. Proc Natl Acad Sci U S A. 2011; 108: 
15163–15168.
 9. Anderson DD, Stover PJ. SHMT1 and SHMT2 are 
functionally redundant in nuclear de novo thymidylate 
biosynthesis. PLoS One. 2009; 4:e5839.
10. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, 
Rabinowitz JD. Quantitative flux analysis reveals folate-
dependent NADPH production. Nature. 2014; 510: 
298–302.
11. Wang L, Lu J, An J, Shi Q, Spitz MR, Wei Q. Polymorphisms 
of cytosolic serine hydroxymethyltransferase and risk of 
lung cancer: a case-control analysis. Lung Cancer. 2007; 
57:143–151.
12. Paone A, Marani M, Fiascarelli A, Rinaldo S, Giardina G, 
Contestabile R, Paiardini A, Cutruzzola F. SHMT1 
knockdown induces apoptosis in lung cancer cells by 
causing uracil misincorporation. Cell Death Dis. 2014; 
5:e1525.
13. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F. Cancer 
incidence and mortality worldwide: sources, methods and 
major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 
136:E359–386.
14. Agrawal S, Kumar A, Srivastava V, Mishra BN. Cloning, 
expression, activity and folding studies of serine 
hydroxymethyltransferase: a target enzyme for cancer 
chemotherapy. J Mol Microbiol Biotechnol. 2003; 6:67–75.
Oncotarget4583www.impactjournals.com/oncotarget
15. Renwick SB, Snell K, Baumann U. The crystal structure of 
human cytosolic serine hydroxymethyltransferase: a target 
for cancer chemotherapy. Structure. 1998; 6:1105–1116.
16. Rao NA, Talwar R, Savithri HS. Molecular 
organization, catalytic mechanism and function of serine 
hydroxymethyltransferase—a potential target for cancer 
chemotherapy. Int J Biochem Cell Biol. 2000; 32:405–416.
17. Webb HK, Matthews RG. 4-Chlorothreonine is substrate, 
mechanistic probe, and mechanism-based inactivator of 
serine hydroxymethyltransferase. J Biol Chem. 1995; 
270:17204–17209.
18. Snell K, Riches D. Effects of a triazine antifolate (NSC 
127755) on serine hydroxymethyltransferase in myeloma 
cells in culture. Cancer Lett. 1989; 44:217–220.
19. Chang WN, Tsai JN, Chen BH, Huang HS, Fu TF. Serine 
hydroxymethyltransferase isoforms are differentially 
inhibited by leucovorin: characterization and comparison 
of recombinant zebrafish serine hydroxymethyltransferases. 
Drug Metab Dispos. 2007; 35:2127–2137.
20. Daidone F, Florio R, Rinaldo S, Contestabile R, di Salvo 
ML, Cutruzzola F, Bossa F, Paiardini A. In silico and 
in vitro validation of serine hydroxymethyltransferase as a 
chemotherapeutic target of the antifolate drug pemetrexed. 
Eur J Med Chem. 2011; 46:1616–1621.
21. Paiardini A, Fiascarelli A, Rinaldo S, Daidone F, 
Giardina G, Koes DR, Parroni A, Montini G, Marani M, 
Paone A, McDermott LA, Contestabile R, Cutruzzolà F, 
Screening and in vitro testing of antifolate inhibitors 
of human cytosolic serine hydroxymethyltransferase. 
ChemMedChem. 2015; 10:490–497.
22. Witschel MSF, Hutzler J, Qu T, Mietzner T, Kreuz K, 
Grossmann K, Aponte R, Höffken HW, Calo F, Ehrhardt T, 
Simon A, Parra Rapado L. (2013). Pyrazolopyrans having 
herbicidal and pharmaceutical properties. PCT Int Appl WO 
2013182472 A1.
23. Witschel MC, Rottmann M, Schwab A, Leartsakulpanich 
U, Chitnumsub P, Seet M, Tonazzi S, Schwertz G, 
Stelzer F, Mietzner T, McNamara C, Thater F, 
Freymond C, et al. Inhibitors of plasmodial serine 
hydroxymethyltransferase (SHMT): cocrystal structures 
of pyrazolopyrans with potent blood- and liver–stage 
activities. J Med Chem. 2015; 58:3117–3130.
24. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. 
Serine and glycine metabolism in cancer. Trends Biochem 
Sci. 2014; 39:191–198.
25. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, 
Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. 
Metabolite profiling identifies a key role for glycine in rapid 
cancer cell proliferation. Science. 2012; 336:1040–1044.
26. Stover PJ, Chen LH, Suh JR, Stover DM, Keyomarsi K, Shane B. 
Molecular cloning, characterization, and regulation of the 
human mitochondrial serine hydroxymethyltransferase 
gene. J Biol Chem. 1997; 272:1842–1848.
27. Tibbetts AS, Appling DR. Compartmentalization of 
Mammalian folate-mediated one-carbon metabolism. Annu 
Rev Nutr. 2010; 30:57–81.
28. Stover PJ, Field MS. Trafficking of intracellular folates. 
Adv Nutr. 2011; 2:325–331.
29. Kabsch W. Integration, scaling, space-group assignment and 
post-refinement. Acta Crystallogr D Biol Crystallogr. 2010; 
66:133–144.
30. Vagin A, Teplyakov A. Molecular replacement with 
MOLREP. Acta Crystallogr D Biol Crystallogr. 2010; 
66:22–25.
31. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, 
Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. 
REFMAC5 for the refinement of macromolecular crystal 
structures. Acta Crystallogr D Biol Crystallogr. 2011; 
67:355–367.
32. Kruschwitz H, Ren S, Di Salvo M, Schirch V. Expression, 
purification, and characterization of human cytosolic 
serine hydroxymethyltransferase. Protein Expr Purif. 
1995; 6:411–416.
33. Schirch L, Ropp M. Serine transhydroxymethylase. Affinity 
of tetrahydrofolate compounds for the enzyme and enzyme-
glycine complex. Biochemistry. 1967; 6:253–257.
34. Schuttelkopf AW, van Aalten DM. PRODRG: a tool 
for high-throughput crystallography of protein-ligand 
complexes. Acta Crystallogr D Biol Crystallogr. 2004; 
60:1355–1363.
35. Thomsen R, Christensen MH. MolDock: a new technique 
for high-accuracy molecular docking. J Med Chem. 2006; 
49:3315–3321.
36. Case JTB DA, Betz RM, Cerutti DS, Cheatham TE, Darden 
TA, Duke RE, Giese TJ, Gohlke AWG H, Homeyer N, Izadi 
S, Janowski P, Kaus J, Kovalenko A, et al. (2015). AMBER 
2015. University of California, San Francisco.
37. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The 
I-TASSER Suite: protein structure and function prediction. 
Nat Methods. 2015; 12:7–8.
38. Gao X, Pujos-Guillot E, Martin JF, Galan P, Juste C, 
Jia W, Sebedio JL. Metabolite analysis of human fecal 
water by gas chromatography/mass spectrometry with 
ethyl chloroformate derivatization. Anal Biochem. 2009; 
393:163–175.
